Intech Biopharm

Intech Biopharm Cash Flow per Share

The Operating Cash Flow per Share of Intech Biopharm (6461.TWO) as of Oct 19, 2026 is -2.65 TWD. In the previous year, Operating Cash Flow per Share was -1.98 TWD — a change of 34.14% (lower).

Cash Flow per Share

-2.65TWD

YoY

34.14%

Last updated:

Operating Cash Flow per Share of Intech Biopharm is 2025 -2.65 TWD. Operating Cash Flow per Share of Intech Biopharm was 2024 -1.98 TWD. It decreases by 34.14% lower compared to the previous year.

The Intech Biopharm Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
-1.71 TWD
Jan 1, 2019
-1.39 TWD
Jan 1, 2020
-1.66 TWD
Jan 1, 2021
-1.73 TWD
Jan 1, 2022
-1.63 TWD
Jan 1, 2023
-1.59 TWD
Jan 1, 2024
-1.98 TWD
Jan 1, 2025
-2.65 TWD
The Intech Biopharm Cash Flow per Share history
YEARCash Flow per ShareYoY
-2.65TWD+34.14%
-1.98TWD+24.25%
-1.59TWD-2.28%
-1.63TWD-5.64%
-1.73TWD+3.82%
-1.66TWD+19.70%
-1.39TWD-18.64%
-1.71TWD+59.98%
-1.07TWD-55.24%
-2.38TWD+39.45%
-1.71TWD+38.82%
-1.23TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Intech Biopharm Stock analysis

What does Intech Biopharm do? Intech Biopharm Ltd is a pharmaceutical company based in Taipei City, Taiwan. The company went public on July 15, 2014, with the ticker symbol 6461.TWO and ISIN TW0006461007. It operates within the Health Care sector, specifically in the Pharmaceuticals industry. Intech Biopharm focuses on developing drugs for obstructive airway diseases, including bronchial asthma and chronic obstructive pulmonary disease. The company's primary products are respiratory drugs, notably the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. These products are distributed both domestically within Taiwan and internationally. The company maintains a website at http://www.intechbiopharm.com/ for further information. Intech Biopharm Ltd is engaged in the research, development, and distribution of pharmaceutical products targeting respiratory conditions, with a focus on innovative inhaler technologies. The firm's operations are centered on addressing unmet medical needs in respiratory care through its specialized drug formulations. Intech Biopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intech Biopharm stock

Operating Cash Flow per Share of Intech Biopharm is -2.65 TWD in 2025.

Operating Cash Flow per Share of Intech Biopharm changed from -1.98 TWD to -2.65 TWD, representing a 34.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Intech Biopharm since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Intech Biopharm

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Intech Biopharm